Skip to main content Skip to navigation
BV711 Rat Anti-Mouse CD140b (PDGFRβ)
Product Details
Down Arrow Up Arrow


BD OptiBuild™
CD140b; PDGF-R-beta; PDGFR-beta; Pdgfrb; platelet-derived growth factor receptor beta
Mouse (Tested in Development)
Rat WI, also known as Wistar (outbred) IgG2a, κ
Recombinant Mouse PDGFRβ Extracellular Domain Protein
Flow cytometry (Qualified)
0.2 mg/ml
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Product Notices

  1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  3. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. BD Horizon Brilliant Violet 711 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
  6. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  7. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
  8. Alexa Fluor™ is a trademark of Life Technologies Corporation.
  9. Cy is a trademark of Global Life Sciences Solutions Germany GmbH or an affiliate doing business as Cytiva.
  10. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  11. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  12. Researchers should determine the optimal concentration of this reagent for their individual applications.
756657 Rev. 1
Antibody Details
Down Arrow Up Arrow
APB5

The APB5 monoclonal antibody specifically recognizes CD140b, the Platelet-Derived Growth Factor Receptor beta chain (PDGFRβ). CD140b is a single-pass type I transmembrane glycoprotein that contains an intracellular tyrosine kinase domain. This receptor is encoded by Pdgfrb and is widely expressed on cells within embryonic tissues and cells of mesenchymal origin in the adult mouse including fibroblasts and vascular smooth muscle cells. CD140b forms homodimers or heterodimeric receptor complexes with CD140a (PDGFRα) upon binding various dimeric Platelet-Derived Growth Factors (PDGF) isoforms that lead to receptor activation. Upon activation, CD140b is autophosphorylated at multiple tyrosine sites and, in turn, initiates several signaling cascades by binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules, such as GRB2, Src, GAP, PI3 kinase, PLCγ, and NCK. These signaling pathways regulate cellular growth and proliferation, survival, differentiation, and migration involved in the development of embryonic tissues, blood vessel formation, wound healing, and in a range of diseases including fibrotic conditions, atherosclerosis, and malignancies.

756657 Rev. 1
Format Details
Down Arrow Up Arrow
BV711
The BD Horizon Brilliant Violet™ 711 (BV711) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 713-nm. BV711, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 710-nm (e.g., a 712/20-nm bandpass filter). The acceptor dye can be excited by the Red (628–640-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV711
Violet 405 nm
407 nm
713 nm
756657 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "756657" on CiteAb

Development References (7)

  1. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine.. Genes Dev. 2008; 22(10):1276-312. (Biology). View Reference
  2. Cossarizza A, Chang HD, Radbruch A, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).. Eur J Immunol. 2019; 49(10):1457-1973. (Clone-specific). View Reference
  3. Cremasco V, Woodruff MC, Onder L, et al. B cell homeostasis and follicle confines are governed by fibroblastic reticular cells.. Nat Immunol. 2014; 15(10):973-81. (Clone-specific: Flow cytometry). View Reference
  4. Ostman A, Heldin CH. Involvement of platelet-derived growth factor in disease: development of specific antagonists.. Adv Cancer Res. 2001; 80:1-38. (Biology). View Reference
  5. Patenaude J, Perreault C. Thymic Mesenchymal Cells Have a Distinct Transcriptomic Profile.. J Immunol. 2016; 196(11):4760-70. (Clone-specific: Flow cytometry). View Reference
  6. Sano H, Sudo T, Yokode M, et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice.. Circulation. 2001; 103(24):2955-60. (Immunogen: Functional assay, Immunohistochemistry, Western blot). View Reference
  7. Sano H, Yokode M, Takakura N, et al. Study on PDGF receptor beta pathway in glomerular formation in neonate mice.. Ann N Y Acad Sci. 2001; 947:303-5. (Clone-specific: Immunohistochemistry, Western blot). View Reference
View All (7) View Less
756657 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.